| 0.08 -0.01 (-11.11%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.14 |
1-year : | 0.17 |
| Resists | First : | 0.12 |
Second : | 0.14 |
| Pivot price | 0.1 |
|||
| Supports | First : | 0.07 |
Second : | 0.06 |
| MAs | MA(5) : | 0.09 |
MA(20) : | 0.1 |
| MA(100) : | 0.12 |
MA(250) : | 1.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.5 |
D(3) : | 23.2 |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 6.69 | Low : | 0.07 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PRPH ] has closed above bottom band by 10.6%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.1 - 0.1 | 0.1 - 0.1 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.
Mon, 01 Jun 2026
ProPhase Labs, Inc. FY 2025: Revenue $4.35M, EPS ($1.74) — 10-K Summary - TradingView
Mon, 01 Jun 2026
[10-K] ProPhase Labs, Inc. Files Annual Report - Stock Titan
Mon, 25 May 2026
PRPH | PROPHASE LABS INC Insider Trading - Quiver Quantitative
Fri, 15 May 2026
ProPhase Labs (NASDAQ: PRPH) delays Q1 2026 10-Q amid 2025 audit - Stock Titan
Wed, 15 Apr 2026
ProPhase Labs Reports Year-End 2025 Results, Highlights - GlobeNewswire
Wed, 15 Apr 2026
$201M in medical claims could start generating cash for ProPhase in Q3 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 5 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -19.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | -272.5 % |
| Operating Margin | -330.3 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | -359.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.4 |
| Sales Per Share | 1.03 |
| EBITDA (p.s.) | -2.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.14 |
| Price to Sales | 0.07 |
| Price to Cash Flow | -0.05 |
| Dividend | 3 |
| Forward Dividend | 0 |
| Dividend Yield | 3750% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|